Exploring 3 High Growth Tech Stocks in the US Market

Simply Wall St

As the U.S. market experiences fluctuations with major indices like the Dow Jones and Nasdaq facing consecutive declines due to concerns over AI stock valuations, investors are closely monitoring high-growth sectors for potential opportunities. In such a dynamic environment, identifying tech stocks that demonstrate strong fundamentals and innovative capabilities can be crucial for navigating the evolving landscape of high-growth investments.

Top 10 High Growth Tech Companies In The United States

NameRevenue GrowthEarnings GrowthGrowth Rating
ADMA Biologics20.01%24.80%★★★★★☆
Palantir Technologies26.95%29.36%★★★★★★
Workday11.18%32.11%★★★★★☆
Circle Internet Group26.05%83.98%★★★★★☆
Gorilla Technology Group32.75%122.61%★★★★★☆
RenovoRx72.94%73.09%★★★★★☆
Pelthos Therapeutics47.44%110.99%★★★★★☆
Zscaler15.72%40.94%★★★★★☆
Duos Technologies Group53.36%152.11%★★★★★☆
Procore Technologies11.61%114.49%★★★★★☆

Click here to see the full list of 74 stocks from our US High Growth Tech and AI Stocks screener.

Below we spotlight a couple of our favorites from our exclusive screener.

Trade Desk (TTD)

Simply Wall St Growth Rating: ★★★★★☆

Overview: The Trade Desk, Inc. is a technology company that provides a global advertising platform and has a market capitalization of approximately $20.28 billion.

Operations: The company generates revenue primarily through its advertising technology platform, which contributed $2.79 billion.

Trade Desk's impressive trajectory is underscored by its recent earnings growth of 42.3% over the past year, significantly outpacing the media industry's 9.5%. With an annual revenue increase projected at 13.9%, TTD is not just keeping pace but exceeding the U.S. market average growth rate of 10.3%. Strategic initiatives like the partnership with DIRECTV to develop Ventura TV OS highlight TTD’s innovative approach to capturing more of the digital advertising market, leveraging technology to enhance user experience and expand market reach. This forward-thinking strategy, combined with a robust R&D focus that aligns with its revenue growth, positions Trade Desk well in a competitive landscape.

TTD Revenue and Expenses Breakdown as at Nov 2025

CyberArk Software (CYBR)

Simply Wall St Growth Rating: ★★★★☆☆

Overview: CyberArk Software Ltd. is a company that specializes in developing and selling software-based identity security solutions and services across various regions including the United States, Israel, the UK, Europe, the Middle East, Africa, and globally; it has a market capitalization of approximately $24.63 billion.

Operations: CyberArk generates revenue primarily from its security software and services segment, which accounts for $1.30 billion. The company focuses on providing identity security solutions across multiple regions worldwide.

Despite recent financial setbacks, CyberArk remains a pivotal player in the cybersecurity sector, particularly with its innovative Secure AI Agents Solution aimed at enhancing AI agent identity security. This move is timely as AI integration deepens across industries, necessitating robust privilege controls to mitigate potential risks associated with autonomous system access. Furthermore, the company's commitment to R&D is evident from its latest product launches and enhancements in machine identity security, which are critical as digital transformations accelerate. CyberArk’s strategic focus on advanced threat detection and identity management positions it to capitalize on growing demands for cybersecurity solutions, although it currently navigates through profitability challenges. With a revenue growth forecast of 15.2% per year outstripping the U.S market average of 10.4%, and an anticipated shift into profitability within three years, CyberArk's trajectory suggests a strong potential for recovery and growth in the evolving tech landscape.

CYBR Earnings and Revenue Growth as at Nov 2025

Neurocrine Biosciences (NBIX)

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Neurocrine Biosciences, Inc. is engaged in the discovery, development, and marketing of pharmaceuticals targeting neurological, neuroendocrine, and neuropsychiatric disorders both in the United States and internationally, with a market cap of $14.44 billion.

Operations: Neurocrine Biosciences focuses on the research, development, and commercialization of pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders. It generates revenue primarily from the sale of these pharmaceuticals, amounting to $2.68 billion.

Neurocrine Biosciences recently showcased its robust pipeline at the Jefferies London Healthcare Conference, despite a setback in its Phase 2 study of NBI-1070770 for major depressive disorder. The company's strategic alliances, like the one with TransThera Sciences to develop NLRP3 inhibitors potentially worth up to $881.5 million, underscore its commitment to addressing complex neurological and neuropsychiatric disorders. Financially, Neurocrine reported a significant year-over-year revenue increase to $794.9 million in Q3 2025 from $622.1 million, with net income rising to $209.5 million from $129.8 million in the same period last year—indicative of strong operational execution and growth trajectory amidst challenging conditions.

NBIX Revenue and Expenses Breakdown as at Nov 2025

Next Steps

Looking For Alternative Opportunities?

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Valuation is complex, but we're here to simplify it.

Discover if CyberArk Software might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.

Access Free Analysis

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com